Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | ESR1 | P03372 | 5/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.44 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | LPL | P06858 | 1/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL868276 | 0.86 | PPARG (0.44) | KDM4EL3MBTL1ESR1ESR2PPARG | |
| SCHEMBL5513086 | 0.85 | KDM4E (0.43) | KDM4EL3MBTL1ESR1ESR2PPARG | |
| SCHEMBL27515092 | 0.84 | KDM4E (0.43) | KDM4EL3MBTL1ESR1ESR2PPARG | |
| SCHEMBL23396073 | 0.82 | KDM4E (0.41) | KDM4EL3MBTL1ESR1ESR2PPARG | |
| SCHEMBL14406088 | 0.82 | ESR1 (0.47) | ESR1ESR2 | |
| SCHEMBL23570309 | 0.82 | KDM4E (0.41) | KDM4EL3MBTL1ESR1ESR2PPARG | |
| SCHEMBL867987 | 0.81 | PPARG (0.43) | KDM4EL3MBTL1ESR1ESR2PPARG | |
| SCHEMBL27668663 | 0.81 | NPC1 (0.44) | KDM4EL3MBTL1ESR1ESR2PPARG | |
| SCHEMBL27915396 | 0.80 | ESR1 (0.42) | ESR1ESR2PPARG | |
| SCHEMBL14116463 | 0.79 | KDM4E (0.42) | KDM4EL3MBTL1ESR1ESR2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119798143-A | Synthesis method of 5-ethyl-2-pyridine ethanol | 安徽尖峰北卡药业有限公司 | 2025-04-11 | — | — | CN | claimed |
| CN-114031548-A | Preparation method of pioglitazone related substance D and related substance D | 湖南增达生物科技有限公司 | 2022-02-11 | — | — | CN | claimed |
| CN-112978890-A | Oilfield sewage flocculant and preparation method thereof | 西安威弗莱环境控制技术有限责任公司 | 2021-06-18 | — | — | CN | claimed |
| CN-119798143-B | Synthesis method of 5-ethyl-2-pyridine ethanol | 安徽尖峰北卡药业有限公司 | 2025-09-30 | — | — | CN | disclosed |
| CN-119798143-B | Synthesis method of 5-ethyl-2-pyridine ethanol | 安徽尖峰北卡药业有限公司 | 2025-09-30 | — | — | CN | disclosed |
| CN-119798143-A | Synthesis method of 5-ethyl-2-pyridine ethanol | 安徽尖峰北卡药业有限公司 | 2025-04-11 | — | — | CN | disclosed |
| CN-119798143-A | Synthesis method of 5-ethyl-2-pyridine ethanol | 安徽尖峰北卡药业有限公司 | 2025-04-11 | — | — | CN | disclosed |
| CN-119798143-A | Synthesis method of 5-ethyl-2-pyridine ethanol | 安徽尖峰北卡药业有限公司 | 2025-04-11 | — | — | CN | disclosed |
| US-11844776-B2 | Composition for treatment and/or prevention of peripheral nerve disorder | OSAKA CITY UNIVERSITY (JP) | 2023-12-19 | — | — | US | disclosed |
| EP-3466421-B1 | COMPOSITION FOR THE TREATMENT OF PERIPHERAL NERVE DISORDERS | UNIV OSAKA CITY (JP) | 2022-11-30 | — | — | EP | disclosed |
| CN-114031548-A | Preparation method of pioglitazone related substance D and related substance D | 湖南增达生物科技有限公司 | 2022-02-11 | — | — | CN | disclosed |
| US-RE36575-E | Pyridine and thiazolidinedione derivatives | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-02-15 | — | — | US | disclosed |
| US-5554758-A | Method for producing ethers | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-09-10 | — | — | US | disclosed |
| EP-0506273-B1 | Method for producing ethers | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1995-05-31 | — | — | EP | disclosed |
| EP-0506273-A2 | Method for producing ethers | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-09-30 | — | — | EP | disclosed |
| EP-0257781-B1 | A METHOD FOR PRODUCING THIAZOLIDINEDIONE DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 1991-09-18 | — | — | EP | disclosed |
| US-4898947-A | Pyridine and thiazolidinedione derivatives | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1990-02-06 | — | — | US | disclosed |
| US-4812570-A | Method for producing thiazolidinedione derivatives | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1989-03-14 | — | — | US | disclosed |
| EP-0257781-A1 | A method for producing thiazolidinedione derivatives | Takeda Chemical Industries, Ltd. (JP) | 1988-03-02 | — | — | EP | disclosed |
| US-4006127-A | Cationic diazacyanine dyestuffs | BAYER AKTIENGESELLSCHAFT (DT) | 1977-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11844776-B2 | Composition for treatment and/or prevention of peripheral nerve disorder | PMP22, PRPH, NGF | KDM4E 3084/4885L3MBTL1 1188/4885ESR1 3450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.